Nine-year outcomes after treatment with SBRT

Katz and Kang will present their 9-year outcomes on 515 patients treated by stereotactic body radiation therapy (SBRT) at the Genitourinary Cancers Symposium tomorrow … READ MORE …

SBRT as focal treatment for isolated, nodal metastasis

A group of Italian researchers has reported preliminary clinical experience of the use of stereotactic body radiation therapy (SBRT), using CyberKnife technology, in the treatment of isolated, nodal metastases as a consequence of prostate cancer. … READ MORE …

Risk for GU side effects higher after SBRT than after IMRT?

A recent, retrospective analysis of Medicare data suggests that men who have first-line stereotactic body radiation therapy (SBRT) are at somewhat higher risk for genitourinary (GU) side effects than men who select intensity-moduated radiation therapy (IMRT). … READ MORE …

Medium-term outcome data on CyberKnife SBRT for localized prostate cancer

A paper in the May issue of the journal Radiation Oncology has provided 6-year outcome data (including quality of life and complications of treatment) after the use of stereotactic body radiation therapy (SBRT) using the CyberKnife system (from the Flushing Radiation Oncology group in Flushing, New York). … READ MORE …

CyberKnife radiation in treatment of intermediate-risk prostate cancer

A new paper in the journal Radiation Oncology provides data on a series of 41 men treated with stereotactic body radiation therapy for intermediate-risk prostate cancer. … READ MORE …

CyberKnife radiation: is it being over-advertised?

Many regular readers may be interested in a blog post by Gary Schwitzer on the MedPage Today web site. It addresses the increasing advertising of CyberKnife radiation therapy (a form of stereotactic body radiation therapy or SBRT) as a first-line treatment for prostate cancer. … READ MORE …

SBRT in men with intermediate-risk, localized prostate cancer

Data reported by Meier et al. and presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) provide some early guidance on the efficacy and safety of sterotactic body radiation therapy (SBRT) in treatment of men with intermediate-risk, localized prostate cancer. … READ MORE …